{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:17:34Z","timestamp":1780467454904,"version":"3.54.1"},"reference-count":81,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bneo.2025.100131","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:04:42Z","timestamp":1750334682000},"page":"100131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Current landscape of frontline and relapsed follicular lymphoma trials"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-6984","authenticated-orcid":false,"given":"Lawrence Cheng Kiat","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9932","authenticated-orcid":false,"given":"Carla","family":"Casulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bneo.2025.100131_bib1","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.bneo.2025.100131_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/bjh.15708","article-title":"Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era","volume":"184","author":"Rivas-Delgado","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bneo.2025.100131_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2018-04-843540","article-title":"Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG","volume":"133","author":"Brady","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bneo.2025.100131_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1470-2045(20)30686-0","article-title":"4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial","volume":"22","author":"Hoskin","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2025.100131_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2021.278766","article-title":"Time for an individualized approach to first-line management of follicular lymphoma","volume":"107","author":"Cartron","year":"2022","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib10","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2022-156790","volume":"140","author":"Northend","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100131_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1200\/JCO.23.01912","article-title":"Long-term follow-up of the RESORT study (E4402): a randomized phase III comparison of two different rituximab dosing strategies for low-tumor burden follicular lymphoma","volume":"42","author":"Kahl","year":"2024","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.bneo.2025.100131_bib12","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1182\/bloodadvances.2020002858","article-title":"Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35\/03 randomized trial","volume":"4","author":"Moccia","year":"2020","journal-title":"Blood Adv"},{"issue":"29","key":"10.1016\/j.bneo.2025.100131_bib13","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","article-title":"Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab","volume":"32","author":"Bittenbring","year":"2014","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2025.100131_bib14","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","article-title":"Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies","volume":"33","author":"Kelly","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2025.100131_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102959","article-title":"Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial","volume":"78","author":"Friedberg","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"18","key":"10.1016\/j.bneo.2025.100131_bib16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100131_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100131_bib19","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100131_bib20","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100131_bib21","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib22","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1182\/blood-2023-177917","article-title":"Subcutaneous mosunetuzumab is active and has a manageable safety profile in patients with previously untreated, low-tumor burden follicular lymphoma: initial results from the phase II morningsun study [abstract]","volume":"142","author":"Flinn","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2025.100131_bib24","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"9873","key":"10.1016\/j.bneo.2025.100131_bib25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"28","key":"10.1016\/j.bneo.2025.100131_bib26","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.22.00843","article-title":"Six-year results from RELEVANCE: lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100131_bib28","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.bneo.2025.100131_bib29","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood.2020010263","article-title":"Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials","volume":"139","author":"Casulo","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1182\/blood-2023-174432","article-title":"Preliminary findings of a phase Ib\/II trial indicate manageable safety and promising efficacy for mosunetuzumab in combination with lenalidomide (M+Len) in previously untreated (1L) follicular lymphoma (FL) [abstract]","volume":"142","author":"Morschhauser","year":"2023","journal-title":"Blood"},{"issue":"9759","key":"10.1016\/j.bneo.2025.100131_bib32","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.bneo.2025.100131_bib33","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"suppl 19","key":"10.1016\/j.bneo.2025.100131_bib34","doi-asserted-by":"crossref","first-page":"TPS7084","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7084","article-title":"EPCORE FL-2: Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma [abstract]","volume":"42","author":"Linton","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bneo.2025.100131_bib36","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s12325-021-01738-2","article-title":"Phase III clinical trials in first-line follicular lymphoma: a review of their design and interpretation","volume":"38","author":"Bachy","year":"2021","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100131_bib38","doi-asserted-by":"crossref","first-page":"TPS7096","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7096","article-title":"Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator\u2019s choice in previously untreated follicular lymphoma (OLYMPIA-1) [abstract]","volume":"42","author":"Birhiray","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100131_bib39","doi-asserted-by":"crossref","first-page":"TPS7099","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7099","article-title":"Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2) [abstract]","volume":"42","author":"Hardin","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100131_bib42","doi-asserted-by":"crossref","first-page":"TPS7579","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7579","article-title":"ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R\/R) follicular lymphoma (FL) [abstract]","volume":"41","author":"Flinn","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100131_bib45","doi-asserted-by":"crossref","first-page":"TPS7588","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7588","article-title":"CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received \u2265 1 line of systemic therapy [abstract]","volume":"40","author":"Nastoupil","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib46","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2023-180092","article-title":"EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R2) vs R2 alone in patients with relapsed or refractory follicular lymphoma [abstract]","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.bneo.2025.100131_bib47","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000975796.49668.c2","article-title":"Trial in progress: phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed\/refractory follicular lymphoma and marginal zone lymphoma (olympia-5) [abstract]","volume":"7","author":"Vitolo","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib48","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1016\/S2152-2650(23)01363-0","article-title":"IBCL-485 a phase III, randomized, double-blind, study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"23","author":"Salles","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"33","key":"10.1016\/j.bneo.2025.100131_bib49","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bneo.2025.100131_bib51","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.bneo.2025.100131_bib52","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100131_bib53","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 2","key":"10.1016\/j.bneo.2025.100131_bib54","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2024-212970","article-title":"Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND) [abstract]","volume":"144","author":"Sehn","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2021-145694","article-title":"Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study [abstract]","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-duration epcoritamab + R2 drives deep and durable responses in patients with relapsed or refractory follicular lymphoma: 2-year follow-up from arm 2 of the Epcore NHL-2 trial [abstract]","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"issue":"uppl 1","key":"10.1016\/j.bneo.2025.100131_bib57","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood-2024-193589","article-title":"Escalating doses of AZD0486, a novel CD19xCD3 T-cell engager, result in high complete remissions with rapid clearance of minimal residual disease in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"144","author":"Hou","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2025.100131_bib58","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib59","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood-2024-203131","article-title":"Golcadomide (GOLCA) \u00b1 rituximab (RTX) demonstrates durable efficacy and is well tolerated in patients (pts) with relapsed\/refractory follicular lymphoma (R\/R FL): updated results from the phase 1\/2 CC-99282-NHL-001 study [abstract]","volume":"144","author":"Chavez","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib60","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2022-162559","article-title":"Iberdomide (CC-220) monotherapy or in combination with an anti-CD20 monoclonal antibody as effective therapy in patients with relapsed\/refractory lymphoma: early results from a phase 1\/2 study [abstract]","volume":"140","author":"Thieblemont","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100131_bib61","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.bneo.2025.100131_bib62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bneo.2025.100131_bib63","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bneo.2025.100131_bib64","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study","volume":"40","author":"Luminari","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bneo.2025.100131_bib65","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100131_bib66","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib67","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.bneo.2025.100131_bib68","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.bneo.2025.100131_bib69","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/jamaoncol.2024.6144","article-title":"Circulating tumor DNA as measurable residual disease in aggressive B-cell lymphoma: a narrative review","volume":"11","author":"Roschewski","year":"2025","journal-title":"JAMA Oncol"},{"issue":"S2","key":"10.1016\/j.bneo.2025.100131_bib70","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.3163_112","article-title":"MRD-negativity after frontline DLBCL therapy: pooled analysis of 6 clinical trials [abstract]","volume":"41","author":"Roschewski","year":"2023","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2023-180007","article-title":"End-of-treatment response assessment after frontline therapy for aggressive B-cell lymphoma: landmark comparison of a singular PET\/CT scan versus ultrasensitive circulating tumor DNA [abstract]","volume":"142","author":"Roschewski","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/blood-2023-187650","article-title":"Prognostic utility of minimal residual disease (MRD) after curative intent induction therapy for DLBCL: a prospective real-world ctDNA study [abstract]","volume":"142","author":"Sworder","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib73","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood-2024-201711","article-title":"Circulating tumor DNA predicts time to first treatment in previously untreated follicular lymphoma: analysis from a prospective clonal evolution study [abstract]","volume":"144","author":"Lakhotia","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2025.100131_bib74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"26","key":"10.1016\/j.bneo.2025.100131_bib75","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2016-02-629063","article-title":"CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date","volume":"127","author":"Park","year":"2016","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2025.100131_bib76","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.bneo.2025.100131_bib77","doi-asserted-by":"crossref","first-page":"TPS7590","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7590","article-title":"MAHOGANY: a phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma [abstract]","volume":"41","author":"Nastoupil","year":"2023","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib78","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2023-188771","article-title":"Efficacy and safety of golcadomide, a novel cereblon E3 ligase modulator (CELMoD) agent, combined with rituximab in a phase 1\/2 open-label study of patients with relapsed\/refractory non-Hodgkin lymphoma [abstract]","volume":"142","author":"Chavez","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.bneo.2025.100131_bib79","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","article-title":"AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma","volume":"37","author":"Leonard","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2025.100131_bib80","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2025.100131_bib81","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.bneo.2025.100131_bib82","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood.2024027347","article-title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: ZUMA-12 study","volume":"145","author":"Chavez","year":"2025","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2025.100131_bib83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.23.01097","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","volume":"42","author":"Iacoboni","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib84","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2024-205671","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes in patients with relapsed\/refractory follicular lymphoma [abstract]","volume":"144","author":"Iacoboni","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib85","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2023-184883","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma [abstract]","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2025.100131_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100044","article-title":"Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy","volume":"1","author":"Tobin","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"5","key":"10.1016\/j.bneo.2025.100131_bib87","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgo.2022.02.005","article-title":"A Young International Society of Geriatric Oncology (YSIOG) review paper","volume":"13","author":"Akhtar","year":"2022","journal-title":"J Geriatr Oncol"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib88","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1182\/blood-2023-188382","article-title":"Frontline management strategy and quality of life in follicular lymphoma: a multi-institutional prospective cohort study [abstract]","volume":"142","author":"Tsang","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.bneo.2025.100131_bib89","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1182\/blood-2024-210968","article-title":"Understanding the patient perspective on treatment preferences for follicular lymphoma [abstract]","volume":"144","author":"Tsang","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2025.100131_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70177","article-title":"Preferences of patients and physicians in the United States for relapsed\/refractory follicular lymphoma treatments","volume":"13","author":"Thomas","year":"2024","journal-title":"Cancer Med"},{"issue":"suppl","key":"10.1016\/j.bneo.2025.100131_bib91","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2024-204187","article-title":"Patient medication preferences in follicular lymphoma (FL) in the United States (USA): a discrete-choice experiment (DCE) [abstract]","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2025.100131_bib92","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1007\/s12325-024-02882-1","article-title":"Quality of life evaluation in patients with follicular cell lymphoma: a real-world study in Europe and the United States","volume":"41","author":"Johnson","year":"2024","journal-title":"Adv Ther"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000664?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328025000664?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T01:40:13Z","timestamp":1764121213000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328025000664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":81,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2950328025000664"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100131","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape of frontline and relapsed follicular lymphoma trials","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2025.100131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100131"}}